Open AccessFurther Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment
Author(s) -
Serge Ferrari,
Peter Butler,
David L. Kendler,
Paul D. Miller,
Christian Roux,
Andrea T Wang,
Shuang Huang,
Rachel B. Wagman,
E. Michael Lewiecki
Publication year - 2019
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2019-00271
Subject(s) - denosumab , medicine , placebo , osteoporosis , bristol myers , randomized controlled trial , bone mineral , incidence (geometry) , relative risk , confidence interval , surgery , physics , alternative medicine , pathology , optics
Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive therapy in osteoporosis is lacking.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom